Who is affected by this change?

This affects Independence Blue Cross Endocrinology, Ophthalmology providers on Commercial plans.

When does this change take effect?

This change is effective Jul 9, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.00.41b, Teprotumumab-trbw (Tepezza®)

Independence Blue Cross·Endocrinology, Ophthalmology·Pharmacy

Effective date

Jul 9, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

The insurance policy for Teprotumumab-trbw (Tepezza®) under the pharmacy category has been reissued with an effective date of July 9, 2025. This is a commercial plan policy update that may affect coverage, prior authorization, or billing requirements for this thyroid eye disease medication.

Action Required

Action needed

By July 9, 2025: Review the full policy details at the provided URL to understand specific changes to Teprotumumab-trbw (Tepezza®) coverage requirements. Billing team should verify any new prior authorization requirements, documentation needs, or coverage criteria that may affect claims processing for this thyroid eye disease medication.

Related policy hubs

Independence Blue Cross policies Endocrinology Ophthalmology